Cardiol Therapeutics Inc.

NASDAQ: CRDL · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Oakville, ONCIK 0001702123Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 42DQ —GM —SS 46

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ filing timeliness, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$24.2M

Employees

Market cap

$121.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$24.2M-33.8M CAD2025

Total assets$17.2M23.6M CAD2025

Liabilities$4.2M5.7M CAD2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Cardiol Therapeutics Inc. earned -$24.2M in FY2025 net income.

Peers · Healthcare

AN2 Therapeutics, Inc.——PepGen Inc.——Humacyte, Inc.26D Unicycive Therapeutics, Inc.31D

Key facts

CEODavid G. Elsley

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersOakville, ON

ExchangeNASDAQ: CRDL

Employees18

IPO date2019-01-15

Latest filings

6-K2026-07-09 6-K2026-06-25 6-K2026-06-23 6-K2026-05-26 6-K2026-05-14 6-K2026-05-11 6-K2026-05-07 6-K2026-04-28

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.